Commerce Bank Cuts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Commerce Bank decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 70,731 shares of the medical research company’s stock after selling 1,309 shares during the quarter. Commerce Bank’s holdings in IQVIA were worth $16,761,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the third quarter valued at $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA during the 3rd quarter valued at about $28,000. Versant Capital Management Inc increased its holdings in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA during the 2nd quarter worth approximately $27,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $194.38 on Thursday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company’s 50-day moving average price is $224.22 and its 200-day moving average price is $227.56. The company has a market cap of $35.28 billion, a PE ratio of 25.51, a price-to-earnings-growth ratio of 1.97 and a beta of 1.51.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Barclays dropped their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and lowered their target price for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Finally, BTIG Research reduced their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $256.50.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.